HIV

Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV

By
1 Mins read
177
0
Share
Reading Time: < 1 minute

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Sunlenca® (lenacapavir), in combination with other antiretroviral(s) (ARV), has been granted approval by the U.S. Read More

177
0
Share
Related posts
HIV

HIV, pregnancy, violence: The three-pronged crisis stealing the future of Africa's girls

By
1 Mins read
Reading Time: < 1 minuteMs Abigael* is not just a statistic. She is a young woman navigating three immediate threats to her life:  the risk of…
HIV

Zambia Must Decide Today: Open Minerals To American Firms Or Lose HIV Support For 1.3 Million

By
1 Mins read
Reading Time: < 1 minuteZambia must choose between granting US mineral access or losing crucial HIV treatment funding. Read More
HIV

Man cured of HIV through groundbreaking transplant from his brother in first-of-its-kind procedure

By
1 Mins read
Reading Time: < 1 minuteA man living with HIV has been cured of the devastating disease in a pioneering transplant, doctors have revealed. Read More
Subscribe to our Blog

Let's stay in touch. Subscribe to our blog and get our best content in your inbox. 

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.